% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

insmhistorian 550 posts  |  Last Activity: May 4, 2016 12:44 PM Member since: Mar 8, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    More iPlex

    by b_leaguered May 3, 2016 9:12 PM
    insmhistorian insmhistorian May 4, 2016 12:44 PM Flag

    Oh, good grief......really??? I quickly scanned through it looking for a date and didn't see it....OK....thank you.......I will go back later and look closer.......LOL

  • Reply to

    More iPlex

    by b_leaguered May 3, 2016 9:12 PM
    insmhistorian insmhistorian May 4, 2016 12:32 PM Flag

    Rocks, can you post the reference site for the December 18, 2018 comment?


  • For those of you who are new Insmed or only know about the Arikayce Paul Harvey might say...."now for the rest of the story".

    To get some of the historical backstory, a good starting point will be Insmed's Form 10-Q for the Quarterly Period ended September 30, 2007. (you can find this Form 10-Q on the Insmed website) Two very important topics to read are:

    1) some other information besides iPlex

    2) the Settlement, License and Development Agreement between Insmed, Tercica, and Genentech

    Even if you don't believe in the discussionher e about iPlex, perhaps you might want to at least catch up on why some people still believe in iPlex

    Happy Reading

  • insmhistorian by insmhistorian May 4, 2016 11:12 AM Flag

    .....$20.65 in April 2015.........$11.25 in August 2014..........$10.40 in July 2013

    Question........wonder if those who recommended purchasing said shares are still gainfully employed??

  • insmhistorian insmhistorian May 2, 2016 7:19 PM Flag

    It does remain to be seen how all this plays out......but just to correct the record slightly.....the settlement was March 2007.....which just proves an age old truism.....that time indeed flies faster the older we get........LOL


  • insmhistorian insmhistorian May 2, 2016 6:47 PM Flag

    Blased, you make some good points. Let me ask you a question......and I certainly have no idea about it myself.....but based upon a couple of your comments, is it possible that some of the job opportunities that Insmed has been posting could serve a dual purpose to meet the future needs for Arikayce....AND iPlex??

  • insmhistorian insmhistorian May 2, 2016 5:21 PM Flag

    I wonder if T will be happy to hear that?

  • Reply to


    by bohemianclubman Apr 22, 2016 12:53 PM
    insmhistorian insmhistorian May 2, 2016 4:21 PM Flag

    Thanks, Bo....found it under bumpy wave. Kind of gives T's comment a different perspective when he says that Mr. Lewis has called iPlex a "historical drug". I'm beginning to wonder, if Mr. Lewis indeed said that, if he wasn't inferring....epic, colossal, stupendous, etc. I'm surprised we haven't heard from T today.

  • Reply to


    by bohemianclubman Apr 22, 2016 12:53 PM
    insmhistorian insmhistorian May 2, 2016 3:41 PM Flag

    Thanks, Bo. Also, when people google what you put, there is also a link to an interesting New York Times article. Bo, I'm surprised we haven't heard from T yet.

  • .....whatever that means. For those not familiar with Insmed's history, let's take a look back to May 25, 2006. for background
    May 25, 2006

    INSMED Announces IPLEX(TM) Availability Nationwide for Children with Severe Short Stature; IPLEX Launch Marked By The First Product Shipments To Patients in States Across the Country

    RICHMOND, Va., May 25, 2006 (BUSINESS WIRE) -- Insmed Incorporated (NASDAQ:INSM) announced today the nationwide availability of IPLEX(TM) (mecasermin rinfabate (rDNA origin). IPLEX was approved as an orphan drug by the Food and Drug Administration in December 2005 for the treatment of growth failure in children with severe primary IGF-I deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. IPLEX is the only once-daily IGF-I replacement therapy available for the treatment of severe primary IGFD.

    "Insmed is very pleased to provide this novel therapeutic protein complex for the treatment of children who suffer from severe primary IGFD," said Philip J. Young, CBO. "It has been a 20-year journey for the many researchers involved in the development of IPLEX, and we are very gratified to finally have the opportunity to provide the only once-daily IGF-I therapy to patients in the United States. It is with great pleasure that we announce that on May 24, 2006 the first US patients with Primary IGFD began receiving IPLEX."

    Primary IGFD is a distinct diagnosis of short stature and is believed to affect as many as 30,000 children in the United States. A subset of these patients is classified as having Severe Primary IGFD, which is estimated to affect 6,000 children. Severe Primary IGFD is a genetic or acquired condition in which patients do not generate sufficient quantities of IGF-I due to defects in the GH receptor/IGF-I pathway. In addition to the growth failure, Severe Primary IGFD can be associated with psychosocial problems. The early recognition and

  • insmhistorian by insmhistorian Apr 27, 2016 1:30 PM Flag

    ......was posted earlier today on this board. Here are the numbers.....DOWN approximately 600,000 shares. This is the lowest share interest figure in over a year.

    Settlement Date Short Interest Avg Daily Share Volume Days To Cover
    4/15/2016 3,908,509 431,447 9.059071
    3/31/2016 4,522,509 378,673 11.943046

  • insmhistorian insmhistorian Apr 27, 2016 12:02 PM Flag

    ".... I've been long since orphan drug status for short stature was awarded and then let slip away... I thought they should have fought harder....."

    Could you please elaborate on this part of your post? iPlex, already approved for GHIS, is caught up in the patent litigation settlement for a little while yet. How could they have fought harder in your estimation?


  • Reply to

    Terry - where did you buy INSM short shares?

    by arikaycerocks Mar 18, 2016 7:41 PM
    insmhistorian insmhistorian Apr 27, 2016 10:11 AM Flag

    Jad, I used to point out spelling deficiencies, but it usually came back to bit me in the in point.....shouldn't "grammerless" be "grammarless" if there is such a word?


  • Reply to

    career job positions

    by iounothjing1 Apr 26, 2016 2:11 PM
    insmhistorian insmhistorian Apr 26, 2016 6:35 PM Flag

    I don't know what else has been removed, but all of the summer intern jobs are now gone......

  • Reply to


    by bohemianclubman Apr 22, 2016 12:53 PM
    insmhistorian insmhistorian Apr 25, 2016 12:45 PM Flag

    Jad, maybe it is just on my computer, but did all of the words of your post make it into the message above? It's a little confusing to me. Could you please resend it?


  • Reply to


    by bohemianclubman Apr 22, 2016 12:53 PM
    insmhistorian insmhistorian Apr 22, 2016 4:00 PM Flag

    For historical context, newer people here may want to google the following for some information posted on the ALS site dated July 2009:

    INSMED To Limit Supply of IPLEX to Existing
    ALS Patients in Current Program

    Zake, I agree with most of what you said. I think where we disagree is where you state that iPLEX's only avenue is as a partner with another larger bio. I believe that is one avenue, and I have always believed in the benefit of partnering. However, in my "pollyanna" scenario, I look at Arikayce, in the here and now, as being the future revenue producer for the future iPLEX studies when the patent lawsuit terms are satisfied in 2018 (or late 2017). My target price is $180/share (as most everyone knows) but may grudgingly accept $90-$120 buyout and try to be happy.......8-)

  • Reply to


    by bohemianclubman Apr 22, 2016 12:53 PM
    insmhistorian insmhistorian Apr 22, 2016 2:46 PM Flag

    Thanks, BO.........VIVA iPLEX

  • Reply to

    Sarepta crushed today...

    by jsblvbjb Apr 21, 2016 10:27 AM
    insmhistorian insmhistorian Apr 21, 2016 11:13 AM Flag

    Duchennes......Insmed has a history with Duchennes. Do you see Insmed revisiting this in the future? For those wondering what I am referring to, see Insmed's press release of June 25, 2009

  • insmhistorian by insmhistorian Apr 20, 2016 5:06 PM Flag

    .......Associate Director, US Marketing

    More information can be found on the Insmed website.

  • I read complaints about Terry's posts being deleted.......I have a different view of that. I think it's cleansing.....kind of like an enema.

    The biggest negative, as far as I'm concerned, is when you reply to his posts and yours are deleted as well. Just start a new thread......paste his original message and then reply to it if you want.

10.95-0.03(-0.27%)10:01 AMEDT